Veteran Israeli venture capitalist Jonathan “Jon” Medved, founder and longtime CEO of OurCrowd—one of Israel’s most influential and globally connected VC firms—has been diagnosed with amyotrophic lateral sclerosis (ALS) and retired from his leadership role, turning to the very health tech innovations he helped fund to preserve his quality of life and communications as the disease progresses. Medved, widely credited as a foundational figure in Israel’s “Startup Nation” ecosystem, disclosed his abrupt ALS diagnosis and emphasized how technologies such as digital avatars and assistive tools developed by startups in the health and AI space are now personally meaningful in helping him stay connected and expressive despite deteriorating physical abilities. As he transitions from executive leadership, Medved remains committed to contributing to the broader tech ecosystem and underscored the ongoing strength of Israeli tech investment and innovation.
Sources: Intellectia.ai, BeamStart
Key Takeaways
• Jon Medved, influential Israeli VC and founder of OurCrowd, has stepped down after an ALS diagnosis and is using health tech innovations he once backed to support his own life and communication.
• Technology such as AI-powered avatars and assistive health devices—developed by startups in Medved’s investment network—is central to his ability to communicate and maintain identity as ALS progresses.
• Despite his retirement from daily leadership, Medved plans to stay engaged in the startup ecosystem and highlights the resilience and continued growth of Israeli tech investment.
In-Depth
Jonathan “Jon” Medved’s diagnosis of amyotrophic lateral sclerosis (ALS) marks a poignant moment for one of Israel’s most prominent venture capital figures and the broader global startup community. Medved, whose career spans decades of entrepreneurship and angel investing, founded OurCrowd in 2013 and helped shape what is often called Israel’s “Startup Nation” by connecting accredited investors worldwide with promising early-stage companies. After decades of backing transformative technologies, including in healthcare, Medved’s own health journey has brought that investment full circle as he now leans on the very tools and innovations he once championed to preserve his quality of life and communication.
ALS, a progressive neurodegenerative disease that attacks motor neurons and ultimately impairs muscle control, came on abruptly for Medved. The diagnosis forced him to step down from his role as CEO of OurCrowd in October 2025, a decision that sent ripples through Israel’s tight-knit tech ecosystem. Publicly sharing his situation in what may be his last extensive interview, Medved described the sudden onset of symptoms and the challenges posed by the disease’s progression.
Yet the narrative is far from purely tragic. Medved’s foresight in backing health tech and AI-driven startups now serves him in a deeply personal way. Among the technologies he has turned to are advanced digital avatars that preserve his face, voice, and mannerisms, enabling him to communicate even as physical abilities decline. These avatars result from collaborations between companies in OurCrowd’s portfolio and AI firms focused on assistive technologies, and they underscore how venture-backed innovation can have profound human impact beyond financial returns.
Medved’s story highlights the intersection of investment and lived experience. What began as strategic bets on promising technologies became life-enhancing tools at a moment of personal adversity. This reality underscores the value of investing not just in market potential, but in solutions that address pressing human needs. The innovations that now support Medved—often rooted in artificial intelligence, digital communication, and assistive health technology—mirror broader trends in which venture capital is increasingly aligned with human-centric breakthroughs.
Despite relinquishing daily leadership duties, Medved has emphasized that he is “far from done” and intends to continue contributing to the entrepreneurial world. His continued involvement reflects a resilience that extends beyond personal health challenges and reinforces the enduring strength of Israeli tech investment, even amid regional tensions and global economic fluctuations. In Medved’s own words, his legacy isn’t just about capital deployed, but the ways in which technology can empower individuals facing daunting life changes.
In the end, Medved’s journey from investor to beneficiary of the innovations he helped fund offers a powerful testament to the potential of venture capital to do more than generate returns: it can change lives. His embrace of technology in the face of ALS also serves as an inspiration to founders and investors alike to prioritize solutions that tackle real, human problems. Through this lens, Medved’s legacy will be remembered not only for financial acumen but for the lasting impact of his vision on both the tech world and the human experience.